YK-11
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Selective androgen receptor modulator with myostatin inhibition.
Reported benefits
Muscle growth beyond genetic limits
Protocols & dosing
Typical dosage: Research protocols (varies).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
YK-11 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Limited human studies
References
No external sources have been catalogued for this article yet.
Related peptides
- ACE-031 — Myostatin inhibitor
- CJC-1295 — Growth hormone, muscle mass, fat loss
- Epithalon + Follistatin Stack — Anti-aging performance combo
- GHRP-4 — Fourth generation GHRP
- Hexarelin — Potent GH releaser
- HGH Fragment 176-191 — Fat loss without GH effects
Categories: Performance & Growth